evipedia.ai
← Back

Oleamide for Health & Longevity

Evidence Review created on 09/22/2026 using AI4L / Opus 5

Also known as: cis-9-octadecenamide, cis-9,10-octadecenoamide, 9-octadecenamide, oleoylamide, ODA

Motivation

Oleamide (oleic acid amide) is a fat-derived molecule the body makes for itself. It was discovered in the fluid around the brain and spinal cord of animals kept awake, where it builds up as the pressure to sleep rises. Because it appears to be part of the body’s own sleep signal, and because it is sold as an inexpensive oral supplement, it draws attention from people who treat sleep as a pillar of long-term health.

The same molecule has a second life in industry, where it is added to plastics to stop films sticking together, and a third as a natural constituent of some plants, mushrooms and bacteria. Beyond sleep, laboratory work has linked it to calmer behaviour, and one small trial tested it for memory in older adults. The rest of that work is animal and cell culture, not people.

This review examines what is known about oleamide as an intervention: how it is thought to act, what the evidence does and does not support, where the risks sit, how it is dosed, and which markers can be tracked. It sets out the evidence and its limits, not a course of action.

Benefits - Risks - Protocol - Conclusion

Sources that give a high-level orientation to oleamide, its discovery, its proposed signalling roles and its practical use.

No content on oleamide could be found on any of the six priority platforms (foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com, lifespan.io). Oleamide is a niche compound whose human trial record runs to a single small study, so it has not attracted coverage from longevity-focused communicators; the list is therefore drawn from narrative reviews by the primary research groups plus the one detailed consumer-facing account that exists.

Grokipedia

Oleamide

Grokipedia’s dedicated oleamide entry assembles the chemistry, the discovery history, the industrial use as a plastics slip agent and the receptor pharmacology in one place, which is useful orientation before reading the primary literature.

Examine

Oleamide

Examine’s dedicated page is short but establishes the compound’s category and primary use case, and states plainly that the sleep evidence rests on injection studies in animals rather than on oral human data.

ConsumerLab

No ConsumerLab article on oleamide exists. Its testing programme covers supplement categories with substantial consumer sales, and oleamide has never been included; the only search hit is an unrelated cosmetics article.

Systematic Reviews

The systematic-review literature that touches oleamide at all.

Oleamide involves a clear trade-off between a claimed sedative benefit and the sedation, temperature and tolerance risks that come with it, and the systematic-review literature represents neither side: no systematic review or meta-analysis addresses oleamide administration for sleep, and none addresses its adverse effects. The single qualifying paper above is a cancer-biomarker review that happens to include oleamide as a measured metabolite.

Mechanism of Action

Oleamide is a fatty acid primary amide: oleic acid whose acid group is an amide. The body makes it from oleoylglycine via peptidylglycine α-amidating monooxygenase (PAM, which converts glycine-extended precursors into amides) and clears it through fatty acid amide hydrolase (FAAH, the enzyme that also degrades anandamide, the brain’s own cannabis-like messenger) (Mueller & Driscoll, 2009).

Two mechanisms compete. The direct account has oleamide activating the cannabinoid receptor CB1 (the receptor that cannabis compounds act on), competing there with an inhibition constant near 1 micromole per litre in rat brain and behaving as a full agonist (Leggett et al., 2004). The entourage account has oleamide acting mainly as a decoy substrate for FAAH, sparing anandamide so that anandamide carries the signal (Lambert & Di Marzo, 1999). Neither is resolved in humans.

Oleamide also raises the affinity of the GABA-A receptor (the main brake on brain activity) for GABA (gamma-aminobutyric acid) at low concentrations (Lees et al., 1998), potentiates serotonin 5-HT1A and 5-HT2A responses (Boger et al., 1998) while blocking 5-HT7 signalling (Hedlund et al., 1999), and closes connexin gap junctions (the direct channels linking glial cells) (Guan et al., 1997).

Selectivity is poor and distribution broad: brain, gut, vessels, immune cells. Behavioural effects in rats fade within 30–60 minutes, implying a short functional half-life; no human half-life is published. Oral oleamide enters through the fatty-acid transporter CD36, is partly cleaved by FAAH inside intestinal cells, and travels in the portal vein bound to albumin (Kobayashi et al., 2022).

Historical Context & Evolution

Oleamide had no therapeutic origin. It was first noted in human serum in the late 1980s, and industry had already been using it for decades as a slip agent in plastic film. Its biological career began in 1995, when a Scripps group isolated an unknown lipid from the cerebrospinal fluid of sleep-deprived cats, identified it as cis-9,10-octadecenoamide, and showed that the synthetic compound induced physiological sleep in rats (Cravatt et al., 1995). That single result moved it from industrial additive to candidate sleep signal, and is why it is now sold for health optimisation.

Through the late 1990s the same group and others mapped the pharmacology: potentiation of serotonin receptor responses, gap-junction closure, strict dependence on the cis double bond, and clearance by FAAH. A 2008 report then showed oleamide leaching from ordinary laboratory plasticware in amounts sufficient to alter enzyme assays (McDonald et al., 2008). This is sometimes described as having discredited the early work, which overstates it: the finding is a contamination caution for cell-free assays, not for the animal sleep experiments, where oleamide was synthesised, weighed and injected.

Opinion has since moved twice. Interest cooled as the receptor profile proved unselective and drug development shifted to FAAH inhibitors instead. It revived on findings in neurogenesis, post-surgical cognition and visceral fat, and in 2024 the first controlled human trial appeared: a dairy-industry study whose microgram dose improved memory scores, but not sleep, against placebo (Sasaki et al., 2024). The target changed, and human evidence now exists: one trial.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High. High requires a human clinical endpoint or a validated clinical surrogate replicated across more than one trial, and only one controlled human administration trial of oleamide exists; the rest of the evidence is rodent behaviour, rodent physiology and cell-culture assays.

Medium 🟩 🟩

Preserved Working and Short-Term Memory

Twelve weeks of 60 micrograms of oral oleamide daily improved memory on the MCI Screen (a validated cognitive test) against placebo in 58 healthy Japanese adults aged 50–75, with immediate and delayed free recall both rising and serum BDNF (brain-derived neurotrophic factor, a nerve-growth signal) above placebo (Sasaki et al., 2024). The trial’s own primary measure, a broader computerised battery, showed no difference. This is a single trial, run and authored by a dairy manufacturer with a commercial interest in oleamide.

Magnitude: The MCI Screen’s overall memory score rose 7.08 ± 5.16 points on a 0–100 scale against −0.58 ± 5.57 on placebo over 12 weeks.

Low 🟩

Shorter Sleep Latency and Better Subjective Sleep Quality

In the same 12-week trial, the oleamide group’s scores on a standard sleep questionnaire improved from baseline for overall quality, subjective quality and sleep latency, but none beat placebo (Sasaki et al., 2024). Rodent work shows shorter onset and more slow-wave sleep at far higher doses (Huitrón-Reséndiz et al., 2001).

Magnitude: The global sleep score fell from a median 5.0 to 3.0 within the oleamide arm while placebo moved 5.0 to 3.5, and the between-group comparison was null.

Speculative 🟨

Reduced Anxiety- and Despair-Like Behaviour

Doses below those that slowed movement reduced anxiety-like behaviour in rats (Fedorova et al., 2001), and repeated dosing cut immobility in mice (Akanmu et al., 2007). Both are animal screens, not human mood outcomes.

Raised Pain Threshold

Oleamide raised pain thresholds in rats, an effect that a cannabinoid receptor blocker reversed in the tail-flick test (Fedorova et al., 2001). Effects lasted 30 to 60 minutes. No human pain study has been done.

Raised Seizure Threshold

Oleamide suppressed chemically induced seizures in mice (Wu et al., 2003) and rats (Nam et al., 2017). Rodent and brain-slice work only; no human seizure data exist.

Neuroprotection Under Mitochondrial and Amyloid Stress

Oleamide preserved cell viability in poisoned rat brain slices through both cannabinoid receptors (Reyes-Soto et al., 2022) and improved maze performance in amyloid-injected mice (Park et al., 2025). Tissue and animal models only.

Hippocampal Neurogenesis Signalling

Oleamide raised doublecortin, a protein marking newly formed nerve cells, in hippocampal progenitor cells via peroxisome proliferator-activated receptor alpha (PPARα, a fat-sensing gene switch) (Roy et al., 2021). Cell-culture and knockout-mouse finding only.

Lower Visceral Fat and Better Glucose Tolerance

Oral oleamide for 12 weeks limited weight gain, abdominal fat and glucose intolerance in mice made sedentary by small-cage housing (Kobayashi et al., 2022). One rodent model, one laboratory. No human metabolic data exist.

Relaxation of Small Arteries ⚠️ Conflicted

Oleamide relaxed isolated rat resistance arteries at low micromolar concentrations, partly through the vessel lining (Hoi & Hiley, 2006). Systemic dosing left rat blood pressure unchanged (Huitrón-Reséndiz et al., 2001). The net reading is unresolved.

Repolarisation of Tumour-Associated Macrophages

In cultured human macrophages, oleamide suppressed the tumour-supporting phenotype and the treated cells’ medium killed breast cancer cells (Wisitpongpun et al., 2024). This is cell-culture work only, with no animal or human tumour outcome.

Benefit-Modifying Factors

  • FAAH C385A carrier status: The common FAAH variant C385A (rs324420) lowers the enzyme’s stability, so carriers clear oleamide and related amides more slowly. Any given oral dose should therefore act longer and more strongly in carriers than in non-carriers.

  • Baseline sleep latency: The proposed benefit is faster sleep onset, so people whose main complaint is a long time to fall asleep have the most room to improve. Those who fall asleep quickly but wake early have little to gain.

  • Baseline endogenous levels: The body’s own oleamide rises with sleep debt. Someone already carrying high levels from chronic short sleep may respond differently from someone well rested, though no study has stratified on this.

  • Sex: Mouse work found clear sex differences in active behaviours after the same oleamide dose, with females and males diverging in the forced-swim test (Akanmu et al., 2007). No human comparison exists.

  • Pre-existing metabolic and inflammatory state: Benefits on abdominal fat and glucose appeared only in animals made metabolically unwell by inactivity. Lean, active people may have no margin for that effect.

  • Age: Slow-wave sleep and the body’s own fatty acid amide signalling both decline with age, so older adults in the target range may have more headroom for a sleep-depth effect — and, equally, more sensitivity to over-sedation.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High. High requires a documented human adverse event or a validated clinical surrogate replicated in more than one trial, and only one controlled human trial of oleamide exists: a 12-week study at 60 micrograms daily that recorded no adverse event attributable to the compound (Sasaki et al., 2024).

Medium 🟥 🟥

No risk reaches Medium either. Medium requires that same class of human outcome from a single trial or from consistent observational data, and the one human trial reported no safety signal at a microgram dose; every item below rests on rodent physiology or cell-culture assays at exposures far above anything tested in people.

Low 🟥

Speculative 🟨

Sedation and Reduced Motor Activity

Oleamide reduced distance travelled in rats, with a median effective dose (ED50, the dose giving half the maximum effect) of 14 mg/kg (Fedorova et al., 2001). Carry-over into waking hours is untested in people.

Fall in Core Body Temperature

Oleamide lowered core temperature dose-dependently in rats, an effect reversed by a GABA-A receptor blocker (Huitrón-Reséndiz et al., 2001; Fedorova et al., 2001). No human thermoregulatory measurement exists.

Fall in Blood Pressure ⚠️ Conflicted

Isolated rat resistance arteries relax to oleamide through cannabinoid and capsaicin-sensitive receptors (Sudhahar et al., 2009), yet systemic dosing left rat blood pressure unchanged (Huitrón-Reséndiz et al., 2001). The net reading is unresolved.

Memory Interference ⚠️ Conflicted

Oleamide sped extinction of avoidance learning in rats (Murillo-Rodríguez et al., 2001), yet impaired memory only at the lower of two mouse doses (Akanmu et al., 2007). The net reading is unresolved.

Rapid Tolerance with Repeated Dosing

Rats became tolerant to oleamide’s behavioural effects after eight days of daily administration, although it induced little physical dependence (Fedorova et al., 2001). Whether nightly human use loses effect is untested.

Increased Food Intake

Oleamide raised food intake in rats over the three hours after injection, as anandamide did (Martínez-González et al., 2004). Whether a nightly oral dose stimulates appetite in people is untested.

Pro-Inflammatory Inflammasome Activation

In cultured human macrophages, oleamide pushed cells toward the inflammatory phenotype and triggered the NLRP3 inflammasome (a protein assembly releasing interleukin-1 beta, IL-1β, a key inflammatory messenger) (Wisitpongpun et al., 2022). Cell-culture evidence only.

Gap-Junction Blockade

Oleamide potently closed gap junctions between glial cells (Guan et al., 1997) and killed glioma (brain tumour) cells by a cannabinoid-receptor-independent route (Torres-Román et al., 2020). Consequences for healthy human tissue are unmeasured.

Industrial-Grade Material and Contaminant Load

Oleamide is manufactured mainly as a plastics additive, and leaches from labware in amounts that alter enzyme assays (McDonald et al., 2008). Industrial lots carry no ingestion specification. The basis is analytical chemistry only.

Risk-Modifying Factors

  • FAAH C385A carrier status: Carriers of this reduced-function variant clear fatty acid amides more slowly, so sedation, temperature drop and next-morning impairment would be expected to be longer-lasting at the same dose.

  • Baseline liver enzymes: Oleamide is cleared by an enzyme concentrated in liver and gut. Raised transaminases (liver enzymes) at baseline signal reduced clearance capacity and make dose-related carry-over more likely.

  • Baseline blood pressure: Oleamide is a potent relaxant of small arteries in rats. Anyone already running low pressure, or taking blood-pressure-lowering medication, sits closer to symptomatic hypotension (abnormally low blood pressure causing dizziness or fainting).

  • Sex: Rodent work shows sex-divergent behavioural responses to identical doses (Akanmu et al., 2007), so the sedation and mood-related effects may not distribute evenly between men and women.

  • Pre-existing conditions: Untreated sleep apnoea (breathing pauses during sleep), chronic obstructive lung disease, a history of substance dependence and any condition causing cognitive impairment all raise the stakes of an unquantified sedative.

  • Age: Older adults in the target range clear fat-soluble compounds more slowly, regulate temperature less well, and fall more easily. Night-time sedation plus a temperature drop is a worse combination at 70 than at 40.

Key Interactions & Contraindications

  • Benzodiazepines and Z-drugs (sedative sleep medicines: triazolam, temazepam, zolpidem, eszopiclone): Caution. Oleamide shortened sleep latency synergistically with a sub-threshold triazolam dose (Mendelson & Basile, 2001). Consequence: excessive sedation and respiratory depression. Mitigation: no concurrent use.

  • Opioids and gabapentinoids (strong pain and nerve-pain medicines: oxycodone, tramadol, gabapentin, pregabalin): Caution. Shared central depressant action plus oleamide’s own cannabinoid-mediated pain relief. Consequence: additive sedation and blunted respiratory drive. Mitigation: no same-night use; an 8-hour separation at minimum.

  • Alcohol: Caution. Both potentiate the GABA-A receptor. Consequence: deeper sedation, impaired coordination, amnesia. Mitigation: no alcohol on nights oleamide is used.

  • Antihypertensives (blood-pressure-lowering medicines: amlodipine, lisinopril, losartan, doxazosin): Monitor. Oleamide relaxes small arteries through nitric oxide, a vessel-relaxing signal. Consequence: additive blood-pressure fall, dizziness on standing. Mitigation: standing blood pressure checks in the first week.

  • Over-the-counter sedating antihistamines (allergy medicines that cause drowsiness: diphenhydramine, doxylamine, promethazine): Caution. Consequence: additive next-morning impairment and, in older adults, confusion. Mitigation: one sedative agent at a time, never stacked.

  • Over-the-counter cannabidiol products: Monitor. Cannabidiol inhibits the enzyme that clears oleamide, raising and prolonging oleamide exposure. Consequence: unpredictable sedation. Mitigation: several hours between doses, and a reduced oleamide dose.

  • Palmitoylethanolamide and other fatty acid amide supplements: Monitor. These compete for the same clearance enzyme, so each raises the other’s levels. Consequence: exaggerated sedation. Mitigation: palmitoylethanolamide in the morning, oleamide at night.

  • Sedating supplements with additive effect (melatonin, valerian, ashwagandha, magnesium glycinate, glycine, lemon balm, kava): Monitor. Consequence: over-sedation and next-morning impairment. Mitigation: one agent added at a time, each held for a week.

  • Blood-pressure-lowering supplements with additive effect (beetroot nitrate, citrulline, hibiscus, garlic extract, high-dose omega-3): Monitor. Consequence: additive hypotension given oleamide’s vasodilatory action in animals. Mitigation: staggered introduction with standing blood pressure tracking.

  • Cannabis and cannabinoid receptor agonists: Caution. Oleamide behaves as a cannabinoid receptor agonist in its own right (Leggett et al., 2004). Consequence: additive psychoactive and cognitive effects. Mitigation: no concurrent use.

Populations who should avoid Oleamide:

  • Pregnancy and lactation — oleamide crosses into milk and alters offspring brain development markers in rodents (Qian et al., 2025); no human data exist.

  • Children and adolescents under 18.

  • Untreated moderate-to-severe obstructive sleep apnoea, with an apnoea-hypopnoea index (the count of breathing pauses per hour of sleep) of 15 or more.

  • Hepatic impairment at Child-Pugh Class B or C (moderate-to-severe liver failure on the standard severity score).

  • Chronic kidney disease at stage 4 or worse (estimated glomerular filtration rate, a measure of kidney filtering capacity, below 30 mL/min/1.73 m²).

  • Symptomatic hypotension or seated systolic blood pressure below 100 mmHg.

  • Active substance use disorder, or current use of any prescribed sedative, opioid or anti-seizure medication.

  • Occupational drivers, pilots and anyone on call overnight.

Risk Mitigation Strategies

  • Quarter-dose start: Protocols start at 25 mg rather than the 100 mg serving and hold there for three nights before increasing, limiting the depth of the unquantified sedation and temperature drop seen in animals.

  • At least 8 hours before waking: Dosing happens at lights-out rather than after a night-time awakening, which keeps the sedation window inside the sleep period and mitigates next-morning motor impairment.

  • A 12-hour no-drive rule on first exposure: Driving and machinery are avoided the morning after each of the first three doses, mitigating the reduced motor activity documented in rodents.

  • Two nights on, one night off: Intermittent dosing mitigates the tolerance that appeared in rats after eight consecutive days, and keeps any loss of effect visible.

  • Only lots with a batch certificate of analysis: Third-party identity and purity testing plus heavy-metal and microbial screens are the minimum, mitigating the contaminant load of industrial-grade material.

  • Standing blood pressure in week one: Seated and standing pressure measured before and 60 minutes after dosing on nights one and seven mitigates additive hypotension with antihypertensive drugs or supplements.

  • One sedative at a time: Other sedating agents are withdrawn before starting, mitigating the additive sedation and respiratory depression risk documented with a low-dose benzodiazepine.

  • Morning confusion or unsteadiness as a stop signal: Residual sedation, unsteadiness or memory lapses count as reasons to stop rather than as titration targets, mitigating the conflicted memory-interference signal.

Therapeutic Protocol

  • Standard regimen: 100 mg of oleamide powder taken orally at night with food; some users add a second 100 mg dose earlier in the evening. This serving size was popularised by Nootropics Depot, which sells the compound.

  • Competing approach — whole-food and extract route: Rather than isolated oleamide, some practitioners use jujube (Ziziphus jujuba) fruit preparations, which contain oleamide among many constituents. Dose of oleamide is then unknown and unstandardised.

  • Competing approach — raise the body’s own levels instead: A pharmacological alternative is to inhibit the clearance enzyme, which raises oleamide and related amides together rather than supplying oleamide (Jain et al., 2022). No such agent is marketed.

  • Best time of day: At lights-out. The sedative, temperature-lowering and motor effects seen in animals all point to night-only dosing; daytime use would deliver the sedation without the benefit.

  • Half-life: No human half-life exists. Behavioural effects in rats resolve within 30–60 minutes and clearance is enzymatic, so the functional duration is short — one reason a single bedtime dose is used rather than divided dosing.

  • Single versus split dosing: A single bedtime dose is standard. Splitting is used only where an earlier wind-down effect is wanted, and it raises total exposure without any evidence of added benefit.

  • Dosing with dietary fat: Absorption runs through a fatty-acid transporter and the compound is carried bound to albumin (Kobayashi et al., 2022). A fat-containing meal or a teaspoon of olive oil is the usual vehicle.

  • Genetic polymorphisms: Carriers of the FAAH C385A variant clear the compound more slowly and may need less. Variants in CYP enzymes (the liver’s main drug-metabolising family) are not implicated, since an amide-splitting enzyme does the work.

  • Sex-based differences: No human dosing comparison exists. Rodent data show sex-divergent behavioural responses to identical doses, so women and men may not need the same amount.

  • Age considerations: Above roughly 65, protocols stay at 25 mg. Slower clearance, weaker temperature regulation and fall risk all argue against the standard 100 mg serving in older adults.

  • Baseline biomarkers: Long sleep latency on a wearable or diary is the marker most likely to move. Normal latency with early waking predicts no response and argues against starting.

  • Pre-existing conditions: Low blood pressure, liver impairment, sleep apnoea and any cognitive impairment all shift the dose downward or rule the compound out entirely.

Discontinuation & Cycling

  • Short-term, not lifelong: Oleamide is used as an episodic sleep aid rather than a continuous longevity agent. Nothing in the evidence base supports indefinite nightly use, and tolerance argues against it.

  • Withdrawal effects: Rats showed little physical dependence after repeated dosing (Fedorova et al., 2001). Rebound insomnia after stopping has not been studied in any species, so it cannot be ruled out.

  • Tapering: No taper is indicated. Given the short functional duration and the absence of dependence in animals, abrupt discontinuation is the norm; a two-week gap makes any rebound obvious.

  • Cycling for efficacy: Cycling is the more defensible pattern. Tolerance appeared in rats within eight days of daily dosing, so two nights on and one off, or three weeks on and one off, keeps the effect measurable.

  • How stopping works: Discontinuation falls on a night with no early obligation, followed by a week of sleep-latency tracking. Latency unchanged off the compound means the dose was not doing the work.

Sourcing and Quality

  • Two grades exist, one specification: The same molecule is sold as a plastics slip agent and as a supplement. Only supplement-grade material carries identity, potency and contaminant testing; industrial lots carry none and are not fit for ingestion.

  • What to look for: A lot-specific certificate of analysis showing high-performance liquid chromatography identity and purity, plus heavy-metal, microbial and residual-solvent screens, produced by an accredited third-party laboratory rather than the seller.

  • The cis isomer is the active one: Activity depends strictly on the cis double bond at position 9; the trans isomer is inactive (Boger et al., 1998). The relevant certificate confirms isomeric identity, not just gross purity.

  • Reputable suppliers: Nootropics Depot publishes batch certificates for its 200 g powder and is the most-documented source; compounding pharmacies do not stock oleamide. This supplier profits from oleamide sales.

  • Storage and oxidation: The powder is waxy and yellows on exposure to air, light and heat. Sealed, cool and dry storage is standard; discoloration signals oxidation of the oleic backbone.

  • Dosing hardware: Bulk powder ships without a scoop and 100 mg cannot be measured visually. A milligram scale is part of the purchase, not an optional accessory.

Practical Considerations

  • Time to effect: Same night, if at all. Animal effects appear within minutes of dosing and resolve within an hour, so a sleep-onset effect either shows up on the first few nights or does not exist for that person.

  • Pitfall — assuming the animal dose transfers: Rodent effects come from 10–20 mg/kg by injection, far above a 100 mg oral human dose, while the one human trial used 60 micrograms. The marketed serving sits between two untested extremes.

  • Pitfall — buying industrial material: Bulk oleamide is cheap because most of it is made for plastics. Buying on price alone reliably lands on material with no ingestion specification.

  • Pitfall — stacking sedatives: Oleamide is usually added on top of melatonin, magnesium and a calming herbal extract, making both benefit and adverse effects impossible to attribute.

  • Regulatory status: Oleamide is not an approved medicine anywhere and has no established dietary-supplement history of use; it is also a permitted plastics additive for food contact. It is sold in the United States as a supplement without pre-market review.

  • Cost and access: Exceptionally cheap — roughly 25 US dollars for 200 g, under two cents per 100 mg dose. Availability is limited to a handful of specialist online vendors.

  • Why the trial record is thin: Oleamide is unpatentable and costs cents per dose: no manufacturer can recover trial costs and no payer will fund a comparison against the prescription sleep medicines it already pays for. The one human trial came from a food company.

Interaction with Foundational Habits

  • Sleep: Direct and potentiating. This is the primary claimed effect: faster onset and more slow-wave sleep in rodents, mediated through cannabinoid and GABA-A signalling. Practical points — dosing at lights-out, at least 8 hours before waking, in a cool room given the temperature drop seen in animals.

  • Nutrition: Direct and potentiating on absorption. Uptake runs through a fatty-acid transporter and the compound circulates bound to albumin, so a fat-containing meal or olive oil improves delivery. Jujube fruit and some edible mushrooms supply small, unquantified amounts naturally.

  • Exercise: Indirect. No study has measured oleamide against training outcomes. The relevant interaction is timing: the sedative and temperature-lowering effects argue against any dose within several hours of a session, and evening training already delays sleep onset.

  • Stress management: Indirect and potentiating. The anxiety-related effects in rodents run through the same cannabinoid pathway that breathing practices and consistent wind-down routines also engage, so the two are complementary rather than redundant. No human stress-hormone measurement exists.

Monitoring Protocol & Defining Success

Before starting, two weeks of baseline data matter more than any laboratory test: the claimed effect is on sleep onset and no biomarker of oleamide exposure is established. Baseline therefore consists of nightly sleep latency, total sleep time and sleep efficiency by diary or wearable, seated and standing blood pressure, and a morning resting heart rate, alongside a basic panel covering liver enzymes, fasting glucose and average blood sugar, kidney filtering capacity and an inflammation marker — the systems where animal and cell data suggest something could move. Ongoing review falls at one week, four weeks and three months, with blood work repeated at three months and then every six to twelve months. Success means a reproducible fall in sleep latency without any rise in next-morning sedation, inflammation or liver enzymes.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Sleep latency Under 20 minutes The primary claimed effect Wearable or diary; average over 14 nights, not single nights
Sleep efficiency 85% or higher Detects fragmented sleep despite faster onset Time asleep divided by time in bed; actigraphy (a wrist-worn movement sensor) is adequate
Morning core temperature 36.4–37.0 °C Animal data show a dose-dependent temperature drop Same time each morning, before rising; wearable skin sensors read low
Seated and standing blood pressure Under 120/80 mmHg seated, no drop over 20 mmHg on standing Oleamide relaxes small arteries in rats Measured 60 minutes post-dose on nights 1 and 7
Resting heart rate 50–65 bpm Screens for a sedation-related nervous-system shift Conventional normal runs to 60–100 bpm. Morning, before rising; compared to personal 14-night baseline
ALT Under 25 U/L (men), under 20 U/L (women) Clearance enzyme is concentrated in liver and gut ALT = alanine aminotransferase, a liver enzyme; conventional upper limits run to 40–55 U/L. Fasting not required
hs-CRP Under 0.5 mg/L Cell data suggest a pro-inflammatory push hs-CRP = high-sensitivity C-reactive protein, a general inflammation marker; conventional cut-off is 3.0 mg/L. Deferred if unwell
Fasting glucose 75–85 mg/dL Rodent data suggest a glucose-tolerance effect Conventional reference range extends to 70–99 mg/dL. 10–12 hour fast; paired with fasting insulin
HbA1c 4.8–5.3% Confirms any glucose change over months HbA1c = haemoglobin A1c, average blood sugar over about three months; conventional target is under 5.7%. Not fasting-dependent
eGFR 90 mL/min/1.73 m² or higher Screens for the impairment that contraindicates use eGFR = estimated glomerular filtration rate, a measure of kidney filtering capacity; conventional normal is 60 mL/min/1.73 m² or higher. No heavy protein or creatine the day before
Endogenous oleamide level No established target exists; track change from the individual’s own baseline instead The only direct exposure marker Research assay only, not clinically available; listed for completeness

Qualitative markers matter more here than any single laboratory value, because the whole benefit claim is subjective:

  • Time to fall asleep as experienced, not just as recorded
  • Residual sedation, headache or unsteadiness on the first hour after waking
  • Daytime energy and the need for an afternoon nap
  • Cognitive clarity, word-finding and short-term recall, given the conflicted memory signal
  • Dream vividness and recall, which cannabinoid-acting compounds commonly alter
  • Mood and irritability across the following day

Emerging Research

  • No ongoing trial administers oleamide: A ClinicalTrials.gov search on 22 September 2026 returned one registered study measuring plasma oleamide — a 120-participant mild-calorie-restriction trial reporting it as a metabolite outcome (NCT02081898) — and none, ongoing or planned, that gives it; the one completed human trial was registered in Japan instead.

  • Replication of the single human trial: Sasaki et al., 2024 is the only controlled human study — 60 micrograms daily for 12 weeks, industry-run, positive on memory and null on sleep against placebo. Independent replication at supplement doses is the decisive open question.

  • Clearance-enzyme inhibition as the tested route instead: A 228-participant Phase 2 trial of a fatty acid amide hydrolase inhibitor in cannabis use disorder (NCT03386487) shows that raising oleamide indirectly is the path drug development actually took, and could strengthen the case for the pathway.

  • Neurogenesis signalling: The doublecortin and peroxisome proliferator-activated receptor alpha axis identified by Roy et al., 2021 would, if reproduced in living animals, move oleamide from sleep aid to candidate neurogenesis agent. It has not yet been replicated outside that group.

  • Cognition after surgery: Wu et al., 2025 report that oleamide reduced postoperative cognitive dysfunction in aged mice through the second cannabinoid receptor, CB2 (found mainly on immune cells). A surgical human trial would test in patients what the one completed trial saw in healthy older adults.

  • Oral pharmacokinetics: Kobayashi et al., 2022 mapped transporter-mediated uptake, first-pass breakdown in gut cells and albumin-bound portal transport. Human absorption studies would settle whether the marketed 100 mg dose reaches the brain at all.

  • Evidence that could weaken the case — inflammation: Wisitpongpun et al., 2022 found oleamide activating the inflammasome and releasing interleukin-1 beta in human macrophages. If this reproduces in living animals, chronic nightly use looks worse, not better.

  • Evidence that could weaken the case — assay contamination: McDonald et al., 2008 showed oleamide leaching from plasticware in bioactive amounts. Re-running key cell-culture findings in glass is an open task that could shrink the mechanistic literature.

  • Enzyme-inhibition findings to treat cautiously: Wattanalaorsomboon et al., 2025 report oleamide inhibiting acetylcholine-degrading and sugar-digesting enzymes in test tubes. Such assays rarely translate, and they are the kind of result plastic leachate can generate.

Conclusion

Oleamide is a fat-derived molecule the body makes and breaks down for itself, and which builds up in the fluid around the brain as the need for sleep grows. That observation is what made it interesting, and it remains the strongest reason to look at it. One small trial in older adults found better memory scores on a tiny daily dose, and a sleep gain no better than placebo. Everything else — faster sleep onset, deeper non-dreaming sleep, calmer behaviour, less pain, protection of nerve cells, less abdominal fat — has been shown only in animals or in laboratory cell cultures.

The main considerations run the other way. The compound acts on many targets rather than one, lowers body temperature and movement in animals, loses its effect within days of repeated dosing, pushes cultured human immune cells toward an inflammatory state, and is manufactured mostly as a plastics additive, so the material itself varies in quality. Its effects add to those of alcohol, sedative medicines and sedating supplements.

The evidence base is unusually thin rather than merely mixed: one controlled study in people, at a dose far below the one sold, and no safety reporting system covering it. Most laboratory work comes from publicly funded academic groups with no product to sell; the one human study was run by a food manufacturer, and the fullest consumer account by a company that sells the powder. The compound is cheap and unpatentable, so little commercial interest pushes the record either way.

Top - Benefits - Risks - Protocol